Mobile

A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Mise à jour : Il y a 5 ans
Référence : NCT01506336

Femme et Homme

  • | Pays :
  • France
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.

Critère d'inclusion

  • Gastro Intestinal Stromal Tumor

Liens